In clinical trials, treatment with setmelanotide results in substantial reduction in hunger and weight loss of ≥10% after 1 year of treatment in 80% of individuals with POMC deficiency and 45% of those with LEPR deficiency [53]. The gene discussed is POMC; the disease is hyperinsulinemic hypoglycemia, familial, 4.